Table 3.
Adipokines in study subjects.
| Measurement | Controls | Newly diagnosed T2D | Established T2D | P value |
|---|---|---|---|---|
| (n = 15) | (n = 15) | (n = 15) | ||
| IL-6 (pg/mL) | 2.84 ± 0.68 | 11.58 ± 2.83 | 12.04 ± 1.20 | <0.0001# |
| (n = 14) | (n = 12) | |||
| TNF-α (pg/mL) | 9.32 ± 2.18 | 9.14 ± 1.15 | 27.93 ± 15.4 | NS |
| (n = 14) | (n = 12) | |||
| PAI-1 (ng/mL) | 3.05 ± 0.56 | 5.23 ± 0.76 | 6.41 ± 1.36 | 0.0305* |
| Total adiponectin (mg/mL) | 6.76 ± 0.78 | 7.48 ± 1.11 | 8.91 ± 2.3 | NS |
| High molecular weight adiponectin (μg/mL) | 1.78 ± 0.26 | 2.33 ± 0.60 | 2.71 ± 1.54 | NS |
| Leptin (ng/mL) | 28.66 ± 7.93 | 46.87 ± 7.96 | 55.93 ± 11.39 | NS |
| TA/L ratio | 1.17 ± 0.76 | 0.24 ± 0.05 | 0.53 ± 0.32 | 0.0340* |
| HMWA/L ratio | 0.49 ± 0.40 | 0.07 ± 0.02 | 0.26 ± 0.22 | 0.0442# |
Data are presented as means ± SE. NS, not significant. *Established T2D versus controls/newly diagnosed T2D. #Newly diagnosed/established T2D versus controls. IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; PAI: plasminogen activator inhibitor 1; TA/L: total adiponectin/leptin ratio; HMWA/L: high molecular weight adiponectin/leptin ratio.